Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer

Multi-center determination of galectin-3 assay performance characteristics:

(2010) Robert H. Christenson et al.   CLINICAL BIOCHEMISTRY

Testicular Cancer Survivorship: Research Strategies and Recommendations

(2010) L. B. Travis et al.   JNCI-Journal of the National Cancer Institute

Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancer

(2009) R Altena et al.   BRITISH JOURNAL OF CANCER

Resveratrol Protects Against Cisplatin-Induced Cardiotoxicity by Alleviating Oxidative Damage

(2009) Jingxuan Wang et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Cisplatin compromises myocardial contractile function and mitochondrial ultrastructure: Role of endoplasmic reticulum stress

(2009) Heng Ma et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography

(2009) S. F. Nagueh et al.   European Journal of Echocardiography

Galectin-3: a novel mediator of heart failure development and progression

(2009) Rudolf A. de Boer et al.   EUROPEAN JOURNAL OF HEART FAILURE

Cisplatin up-regulates ICAM-1 expression in endothelial cell via a NF-κB dependent pathway

(2008) Minghua Yu et al.   CANCER SCIENCE

Medical Treatment of Advanced Testicular Cancer

(2008) Darren R. Feldman   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Left Ventricular Ejection Fraction and Cardiotoxicity: Is Our Ear Really to the Ground?

(2008) Michael S. Ewer et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarkers in Heart Failure

(2008) Eugene Braunwald   NEW ENGLAND JOURNAL OF MEDICINE